CytoDyn Inc. (CYDY) Financial Statements (2024 and earlier)

Company Profile

Business Address 1111 MAIN STREET, SUITE 660
VANCOUVER, WA 98660
State of Incorp. DE
Fiscal Year End May 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

8/31/2023
MRQ
5/31/2023
11/30/2022
MRQ
5/31/2022
5/31/2021
5/31/2020
5/31/2019
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments2,5412,4034,23133,94314,2822,613
Cash and cash equivalents2,5412,4034,23133,94314,2822,613
Restricted cash and investments6,507200  10854
Inventory, net of allowances, customer advances and progress billings    93,479  
Inventory    93,479  
Prepaid expense1,1672,8545,198616498107
Other undisclosed current assets5901,0941,0861,54322,0371,796
Total current assets:10,8056,55110,515129,58136,8275,369
Noncurrent Assets
Inventory, Noncurrent   17,929   
Operating lease, right-of-use asset   536712176
Property, plant and equipment   731345529
Intangible assets, net (including goodwill)   1321,65313,45615,475
Intangible assets, net (excluding goodwill)   1321,65313,45615,475
Other noncurrent assets487523    
Total noncurrent assets:48752318,6702,49913,68715,505
TOTAL ASSETS:11,2927,07429,185132,08050,51420,874
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities78,96680,53379,42974,55637,61918,041
Interest and dividends payable12,8509,9514,6541,274213
Employee-related liabilities4961,5044,0056,8661,589
Accounts payable62,72567,18767,97465,89729,47916,239
Accrued liabilities16,241     
Debt34,41736,93136,24162,747 3,586
Derivative instruments and hedges, liabilities79     
Estimated litigation liability1681662,00611,008  
Other liabilities 2001,6244,060  
Other undisclosed current liabilities6,1664,8603,8611756,8825,300
Total current liabilities:119,796122,690123,161152,54644,50126,926
Noncurrent Liabilities
Long-term debt and lease obligation   4225528,494455
Long-term debt, excluding current maturities     8,431455
Liabilities, other than long-term debt283353   2,407
Operating lease, liability28335342255263
Derivative instruments and hedges, liabilities      2,407
Other undisclosed noncurrent liabilities 714 (422)(552)(63) 
Total noncurrent liabilities:9973534225528,4942,862
Total liabilities:120,793123,043123,583153,09852,99529,788
Equity
Equity, attributable to parent, including:(109,501)(115,969)(94,398)(21,018)(2,480)(8,914)
Common stock919825720626519330
Treasury stock, value     (0)(0)
Additional paid in capital731,270692,558671,013489,650351,711220,120
Accumulated deficit(841,690)(809,352)(766,131)(511,294)(354,711)(229,363)
Other undisclosed equity, attributable to parent     00
Total equity:(109,501)(115,969)(94,398)(21,018)(2,480)(8,914)
TOTAL LIABILITIES AND EQUITY:11,2927,07429,185132,08050,51420,874

Income Statement (P&L) ($ in thousands)

8/31/2023
TTM
5/31/2023
11/30/2022
TTM
5/31/2022
5/31/2021
5/31/2020
5/31/2019
Revenues  266 500 
Gain (loss) on disposition of assets for financial service operations(8,750)(8,601)    
Other income     500 
Cost of revenue(20,633)(20,633)(53)(1,797)  
Cost of goods and services sold(20,633)(20,633)(73,490)(1,797)  
Gross profit:(20,633)(20,633)213(1,797)500 
Operating expenses(19,943)(31,639)(72,127)(102,799)(74,647)(55,852)
Other undisclosed operating loss  (73,490)   
Operating loss:(40,576)(52,272)(145,404)(104,596)(74,147)(55,852)
Nonoperating income
(Investment Income, Nonoperating)
    251,671
Interest and debt expense(39,248)(27,542)(65,416)(31,474)(18,220)(4,832)
Loss from continuing operations before equity method investments, income taxes:(79,824)(79,814)(210,820)(136,068)(92,362)(59,014)
Other undisclosed loss from continuing operations before income taxes    (18,606)(32,042) 
Loss from continuing operations before income taxes:(79,824)(79,814)(210,820)(154,674)(124,403)(59,014)
Income tax benefit      2,827
Loss from continuing operations:(79,824)(79,814)(210,820)(154,674)(124,403)(56,187)
Loss before gain (loss) on sale of properties:(53,319)(210,820)(154,674)(124,403)(56,187)
Net loss attributable to parent:(79,824)(79,814)(210,820)(154,674)(124,403)(56,187)
Preferred stock dividends and other adjustments(1,495)(755)1,628   
Other undisclosed net loss available to common stockholders, basic(5,417)(5,294)(3,256)   
Net loss available to common stockholders, diluted:(86,736)(85,863)(212,448)(154,674)(124,403)(56,187)

Comprehensive Income ($ in thousands)

8/31/2023
TTM
5/31/2023
11/30/2022
TTM
5/31/2022
5/31/2021
5/31/2020
5/31/2019
Net loss:(79,824)(79,814)(210,820)(154,674)(124,403)(56,187)
Comprehensive loss, net of tax, attributable to parent:(79,824)(79,814)(210,820)(154,674)(124,403)(56,187)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: